Home › Companies › ALNYLAM PHARMACEUTICALS INC. › 2023-2024

ALNYLAM PHARMACEUTICALS INC. 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and ALNYLAM PHARMACEUTICALS INC.’s Form 8-K, filed May 20, 2024 (Item 5.07 on EDGAR). Page generated November 1, 2026.

6Reported items
480Asset managers
3,801Fund votes
May 16, 2024Meeting date

Results at a glance

Meeting of May 16, 2024: 6 items on ALNYLAM PHARMACEUTICALS INC.’s Form 8-K, filed May 20, 2024: 4 elected · 2 approved.

Material dissent

None.

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore ALNYLAM PHARMACEUTICALS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by ALNYLAM PHARMACEUTICALS INC.

These tallies are ALNYLAM PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 20, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

ALNYLAM PHARMACEUTICALS INC. — official shareholder meeting results, meeting held May 16, 2024
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Support (of votes cast)	Reported outcome	Voting standard
Elect Director: Dennis A. Ausiello, M.D.	103,971,532	8,960,235	14,285	--	4,991,057	92%	Elected	—
Elect Director: Olivier Brandicourt, M.D.	106,444,201	6,487,472	14,379	--	4,991,057	94%	Elected	—
Elect Director: Peter N. Kellogg	108,577,015	4,354,577	14,460	--	4,991,057	96%	Elected	—
Elect Director: David E.I. Pyott	102,273,209	10,658,278	14,565	--	4,991,057	91%	Elected	—
The terms of office of the following directors continued after the Annual Meeting: Carolyn R. Bertozzi, M.D.	106,783,262	6,133,628	29,162	--	4,991,057	95%	Approved	—
3. The appointment by the Company's Board of Directors of PricewaterhouseCoopers LLP as the Company's independent auditors for the fiscal year ending December 31, 2024	114,460,115	3,456,326	20,668	--	0	97%	Approved	—

This meeting is also recorded here as May 17, 2024; both records come from the same filing, so the date should be checked against it.

Source: ALNYLAM PHARMACEUTICALS INC., Form 8-K, filed with the SEC on May 20, 2024 — read the filing on EDGAR.

How asset managers voted at the ALNYLAM PHARMACEUTICALS INC. 2023-2024 meeting

Each item below shows how the 480 asset managers that disclosed a ALNYLAM PHARMACEUTICALS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of ALNYLAM PHARMACEUTICALS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. Elect Director: David E.I. Pyott

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 7 wordings of this item as funds reported it.

91% Majority: yes · of votes cast

FOR 91%

FOR: 102,273,209AGAINST: 10,658,278

Details: description as filed, official tally, votes by 128 asset managers

Description as filed by funds: To elect the following nominees as Class II directors of Alnylam: David E.I. Pyott

ALNYLAM PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: David E.I. Pyott”): 102,273,209 for, 10,658,278 against, per its Form 8-K filed May 20, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The Company's stockholders re-elected the four persons listed below as Class II directors, each to serve until the Company's 2027 annual meeting of stockholders or until his successor is duly elected and qualified.”
Support: 91% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 128 asset managers below reported 60,356,958 for, 5,409,246 against, 6,114 abstained.

FOR

FOR: 60,356,958AGAINST: 5,409,246ABSTAIN: 6,114

Largest asset managers voting on “To elect the following nominees as Class II directors of Alnylam: David E.I. Pyott” at ALNYLAM PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Against	Vote
Vanguard	18,597,294	0	For
Capital Group	14,436,051	0	For
Fidelity	9,412,385	0	For
T. Rowe Price	0	4,521,656	Against
BlackRock	3,341,538	0	For
AMCAP FUND	3,331,971	0	For
Dodge & Cox	2,854,341	0	For
American Century	1,028,316	0	For
JPMorgan	1,000,946	0	For
NEW ECONOMY FUND	888,487	0	For
State Street	571,157	130	For
Jackson National	306,432	251,010	Mixed
TIAA	539,348	0	For
Charles Schwab	442,624	0	For
Equitable	172,037	51,639	Mixed
First Trust	219,863	0	For
BNY Mellon	206,703	0	For
OLD WESTBURY FUNDS INC	194,004	0	For
CARILLON SERIES TRUST	192,539	0	For
MassMutual	1,795	187,332	Against
Aberdeen	174,015	0	For
John Hancock	124,098	49,226	Mixed
FRANKLIN STRATEGIC SERIES	148,400	0	For
Federated Hermes	147,700	0	For
Dimensional	136,870	0	For

Showing the 25 largest of 128 asset managers. See all 128 in the interactive database.

2. Elect Director: Dennis A. Ausiello, M.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 7 wordings of this item as funds reported it.

92% Majority: yes · of votes cast

FOR 92%

FOR: 103,971,532AGAINST: 8,960,235

Details: description as filed, official tally, votes by 128 asset managers

Description as filed by funds: To elect the following nominees as Class II directors of Alnylam: Dennis A. Ausiello, M.D.

ALNYLAM PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Dennis A. Ausiello, M.D.”): 103,971,532 for, 8,960,235 against, per its Form 8-K filed May 20, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The Company's stockholders re-elected the four persons listed below as Class II directors, each to serve until the Company's 2027 annual meeting of stockholders or until his successor is duly elected and qualified.”
Support: 92% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 128 asset managers below reported 60,426,871 for, 5,339,333 against, 6,114 abstained.

FOR

FOR: 60,426,871AGAINST: 5,339,333ABSTAIN: 6,114

Largest asset managers voting on “To elect the following nominees as Class II directors of Alnylam: Dennis A. Ausiello, M.D.” at ALNYLAM PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Against	Vote
Vanguard	18,597,294	0	For
Capital Group	14,436,051	0	For
Fidelity	9,412,385	0	For
T. Rowe Price	0	4,521,656	Against
BlackRock	3,341,538	0	For
AMCAP FUND	3,331,971	0	For
Dodge & Cox	2,854,341	0	For
American Century	1,028,316	0	For
JPMorgan	1,000,946	0	For
NEW ECONOMY FUND	888,487	0	For
State Street	571,074	213	For
Jackson National	306,432	251,010	Mixed
TIAA	539,348	0	For
Charles Schwab	442,624	0	For
Equitable	172,037	51,639	Mixed
First Trust	219,863	0	For
BNY Mellon	206,703	0	For
OLD WESTBURY FUNDS INC	194,004	0	For
CARILLON SERIES TRUST	192,539	0	For
MassMutual	1,795	187,332	Against
Aberdeen	174,015	0	For
John Hancock	124,098	49,226	Mixed
FRANKLIN STRATEGIC SERIES	148,400	0	For
Federated Hermes	147,700	0	For
Dimensional	136,870	0	For

Showing the 25 largest of 128 asset managers. See all 128 in the interactive database.

3. Elect Director: Olivier Brandicourt, M.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 7 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%

FOR: 106,444,201AGAINST: 6,487,472

Details: description as filed, official tally, votes by 128 asset managers

Description as filed by funds: To elect the following nominees as Class II directors of Alnylam: Olivier Brandicourt, M.D.

ALNYLAM PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Olivier Brandicourt, M.D.”): 106,444,201 for, 6,487,472 against, per its Form 8-K filed May 20, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The Company's stockholders re-elected the four persons listed below as Class II directors, each to serve until the Company's 2027 annual meeting of stockholders or until his successor is duly elected and qualified.”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 128 asset managers below reported 62,548,914 for, 3,217,290 against, 6,114 abstained.

FOR

FOR: 62,548,914AGAINST: 3,217,290ABSTAIN: 6,114

Largest asset managers voting on “To elect the following nominees as Class II directors of Alnylam: Olivier Brandicourt, M.D.” at ALNYLAM PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Against	Vote
Vanguard	18,597,294	0	For
Capital Group	14,436,051	0	For
Fidelity	9,412,385	0	For
T. Rowe Price	1,664,187	2,857,469	Mixed
BlackRock	3,341,538	0	For
AMCAP FUND	3,331,971	0	For
Dodge & Cox	2,854,341	0	For
American Century	1,028,316	0	For
JPMorgan	1,000,946	0	For
NEW ECONOMY FUND	888,487	0	For
State Street	571,225	62	For
Jackson National	557,442	0	For
TIAA	539,348	0	For
Charles Schwab	442,624	0	For
Equitable	172,037	51,639	Mixed
First Trust	219,863	0	For
BNY Mellon	14,353	192,350	Mixed
OLD WESTBURY FUNDS INC	194,004	0	For
CARILLON SERIES TRUST	192,539	0	For
MassMutual	189,127	0	For
Aberdeen	174,015	0	For
John Hancock	124,098	49,226	Mixed
FRANKLIN STRATEGIC SERIES	148,400	0	For
Federated Hermes	147,700	0	For
Dimensional	136,870	0	For

Showing the 25 largest of 128 asset managers. See all 128 in the interactive database.

4. Elect Director: Peter N. Kellogg

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 7 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%

FOR: 108,577,015AGAINST: 4,354,577

Details: description as filed, official tally, votes by 128 asset managers

Description as filed by funds: To elect the following nominees as Class II directors of Alnylam: Peter N. Kellogg

ALNYLAM PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Peter N. Kellogg”): 108,577,015 for, 4,354,577 against, per its Form 8-K filed May 20, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The Company's stockholders re-elected the four persons listed below as Class II directors, each to serve until the Company's 2027 annual meeting of stockholders or until his successor is duly elected and qualified.”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 128 asset managers below reported 62,773,501 for, 2,992,703 against, 6,114 abstained.

FOR

FOR: 62,773,501AGAINST: 2,992,703ABSTAIN: 6,114

Largest asset managers voting on “To elect the following nominees as Class II directors of Alnylam: Peter N. Kellogg” at ALNYLAM PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Against	Vote
Vanguard	18,597,294	0	For
Capital Group	14,436,051	0	For
Fidelity	9,412,385	0	For
T. Rowe Price	1,664,187	2,857,469	Mixed
BlackRock	3,341,538	0	For
AMCAP FUND	3,331,971	0	For
Dodge & Cox	2,854,341	0	For
American Century	1,028,316	0	For
JPMorgan	1,000,946	0	For
NEW ECONOMY FUND	888,487	0	For
State Street	571,225	62	For
Jackson National	557,442	0	For
TIAA	539,348	0	For
Charles Schwab	442,624	0	For
Equitable	172,037	51,639	Mixed
First Trust	219,863	0	For
BNY Mellon	206,703	0	For
OLD WESTBURY FUNDS INC	194,004	0	For
CARILLON SERIES TRUST	192,539	0	For
MassMutual	189,127	0	For
Aberdeen	174,015	0	For
John Hancock	124,098	49,226	Mixed
FRANKLIN STRATEGIC SERIES	148,400	0	For
Federated Hermes	147,700	0	For
Dimensional	136,870	0	For

Showing the 25 largest of 128 asset managers. See all 128 in the interactive database.

5. To approve, in a non-binding advisory vote, the compensation of Alnylam's named executive officers.

No official match Fund totals may overlapSECTION 14A SAY-ON-PAY VOTES

Combines 14 wordings of this item as funds reported it.

96% Fund and manager reports combined; may count the same shares twice · no official result

FOR

Details: votes by 476 asset managers

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports: 121 asset managers voting on “To approve, in a non-binding advisory vote, the compensation of Alnylam's named executive officers.” at ALNYLAM PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Against	Vote
Vanguard	18,597,294	0	For
Capital Group	14,436,051	0	For
Fidelity	9,412,385	0	For
T. Rowe Price	4,464,575	57,081	For
BlackRock	3,341,538	0	For
AMCAP FUND	3,331,971	0	For
Dodge & Cox	2,854,341	0	For
American Century	0	1,028,316	Against
JPMorgan	1,000,946	0	For
NEW ECONOMY FUND	888,487	0	For
State Street	571,287	0	For
Jackson National	557,442	0	For
TIAA	539,348	0	For
Charles Schwab	442,624	0	For
Equitable	223,676	0	For
First Trust	219,863	0	For
BNY Mellon	14,353	192,350	Mixed
OLD WESTBURY FUNDS INC	194,004	0	For
CARILLON SERIES TRUST	192,539	0	For
MassMutual	189,127	0	For
Aberdeen	0	174,015	Against
John Hancock	173,324	0	For
FRANKLIN STRATEGIC SERIES	148,400	0	For
Federated Hermes	147,700	0	For
Dimensional	136,870	0	For

Fund voting reports, all 121 managers: 64,169,018 for, 1,560,913 against, 4,534 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 386 asset managers voting on “To approve, in a non-binding advisory vote, the compensation of Alnylam's named executive officers.” at ALNYLAM PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Against	Vote
Capital Group	16,553,248	0	For
Fidelity	9,796,707	10,224	For
Wellington	6,981,073	0	For
T. Rowe Price	6,394,932	115,403	For
BlackRock	4,466,521	0	For
Dodge & Cox	3,540,790	0	For
Capital Research Global Investors	3,136,845	0	For
State Street	2,765,595	0	For
BAILLIE GIFFORD & CO LTD	2,426,931	0	For
GEODE CAPITAL MANAGEMENT, LLC	1,987,575	0	For
Man Group plc	1,821,640	0	For
BAILLIE GIFFORD OVERSEAS LTD	1,570,444	0	For
American Century	0	1,123,799	Against
Northern Trust	730,992	2,751	For
PICTET ASSET MANAGEMENT SA	686,264	0	For
Legal & General Investment Management Ltd	0	617,424	Against
Nuveen	544,190	0	For
UBS	0	521,780	Against
Charles Schwab	501,586	0	For
Amundi	0	351,577	Against
Newton Investment Management North America, LLC	0	331,533	Against
Mitsubishi UFJ Trust & Banking Corp	317,350	0	For
MELLON INVESTMENTS Corp	311,441	0	For
Vanguard	296,362	0	For
Candriam S.C.A.	286,898	0	For

Institutional-manager reports, all 386 managers: 73,638,611 for, 4,679,971 against, 1,433 not voted, 3 unknown. Showing the 25 largest; see all in the interactive database.

6. 3. The appointment by the Company's Board of Directors of PricewaterhouseCoopers LLP as the Company's independent…

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 8 wordings of this item as funds reported it.

97% Approved · of votes cast

FOR 97%

FOR: 114,460,115AGAINST: 3,456,326

Details: description as filed, official tally, votes by 129 asset managers

Description as filed by funds: To ratify the appointment of PricewaterhouseCoopers LLP, an independent registered public accounting firm, as Alnylam's independent auditors for the fiscal year ending December 31, 2024.

ALNYLAM PHARMACEUTICALS INC.’s own tally for this item (“3. The appointment by the Company's Board of Directors of PricewaterhouseCoopers LLP as the Company's independent auditors for the fiscal year ending December 31, 2024”): 114,460,115 for, 3,456,326 against — passed, per its Form 8-K filed May 20, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders ratified the appointment by the Company's Board of Directors of PricewaterhouseCoopers LLP as the Company's independent auditors for the fiscal year ending December 31, 2024.”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 129 asset managers below reported 65,543,601 for, 223,603 against, 5,207 abstained.

FOR

FOR: 65,543,601AGAINST: 223,603ABSTAIN: 5,207

Largest asset managers voting on “To ratify the appointment of PricewaterhouseCoopers LLP, an independent registered public accounting firm, as ” at ALNYLAM PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Against	Vote
Vanguard	18,597,294	0	For
Capital Group	14,436,051	0	For
Fidelity	9,412,385	0	For
T. Rowe Price	4,521,656	0	For
BlackRock	3,341,538	0	For
AMCAP FUND	3,331,971	0	For
Dodge & Cox	2,854,341	0	For
American Century	1,028,316	0	For
JPMorgan	1,000,946	0	For
NEW ECONOMY FUND	888,487	0	For
State Street	571,204	83	For
Jackson National	557,442	0	For
TIAA	539,348	0	For
Charles Schwab	442,624	0	For
Equitable	223,676	0	For
First Trust	219,863	0	For
BNY Mellon	206,703	0	For
OLD WESTBURY FUNDS INC	194,004	0	For
CARILLON SERIES TRUST	192,539	0	For
MassMutual	189,127	0	For
Aberdeen	0	174,015	Against
John Hancock	173,324	0	For
FRANKLIN STRATEGIC SERIES	148,400	0	For
Federated Hermes	147,700	0	For
Dimensional	136,870	0	For

Showing the 25 largest of 129 asset managers. See all 129 in the interactive database.

Largest ALNYLAM PHARMACEUTICALS INC. shareholders voting in 2023-2024

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 126,463,000 shares outstanding at the time of that meeting.

Fund voting reports: top ALNYLAM PHARMACEUTICALS INC. shareholders by shares voted on “To ratify the appointment of PricewaterhouseCoopers LLP, an independent registered public…”, 2023-2024
#	Asset manager	% of shares outstanding
1	Vanguard	14.71%
2	Capital Group	11.42%
3	Fidelity	7.44%
4	T. Rowe Price	3.58%
5	BlackRock	2.64%
6	AMCAP FUND	2.63%
7	Dodge & Cox	2.26%
8	American Century	0.81%
9	JPMorgan	0.79%
10	NEW ECONOMY FUND	0.70%

Institutional-manager reports: top ALNYLAM PHARMACEUTICALS INC. shareholders by shares voted on “To approve, in a non-binding advisory vote, the compensation of Alnylam's named executive…”, 2023-2024
#	Asset manager	% of shares outstanding
1	Capital Group	13.09%
2	Fidelity	7.75%
3	Wellington	5.52%
4	T. Rowe Price	5.15%
5	BlackRock	3.53%
6	Dodge & Cox	2.80%
7	Capital Research Global Investors	2.48%
8	State Street	2.19%
9	BAILLIE GIFFORD & CO LTD	1.92%
10	GEODE CAPITAL MANAGEMENT, LLC	1.57%

Reported ALNYLAM PHARMACEUTICALS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.

ALNYLAM PHARMACEUTICALS INC. holdings and ownership disclosed for the 2023-2024 proxy season
Holder	% outstanding	Disclosure
FMR (Fidelity)	13.26%	13F
Vanguard Group	10.73%	13F
BlackRock	7.83%	13F
Wellington Management	5.70%	13F
JPMorgan Chase	3.59%	13F
T. Rowe Price	2.91%	13F
Capital International	2.89%	13F
State Street	2.52%	13F
Geode Capital	1.58%	13F
Norges Bank	1.20%	13F

Percentages above are of 126,463,000 shares outstanding, as reported by ALNYLAM PHARMACEUTICALS INC. on its Form 10-Q dated March 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ALNYLAM PHARMACEUTICALS INC.’s 10-Q dated March 31, 2024. This page is a static snapshot rebuilt weekly on November 1, 2026; a live search always shows the current data.

At ALNYLAM PHARMACEUTICALS INC.'s shareholder meeting held May 16, 2024, in the 2023-2024 proxy season, 480 asset managers reported how they voted in their SEC Form N-PX filings, covering 3,801 separate fund positions. Their filings are grouped here into 6 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. ALNYLAM PHARMACEUTICALS INC.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — To approve, in a non-binding advisory vote, the compensation of Alnylam's named executive… — the reporting funds and managers cast 96% of the shares they voted in favour (FOR divided by FOR plus AGAINST plus WITHHELD; abstained and unvoted shares are excluded because neither took a side). Fund and manager reports are combined in it and may count the same shares twice: it adds fund reports to institutional-manager reports, which can cover the same shares. It is not the company's certified result.

ALNYLAM PHARMACEUTICALS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.

Download data (CSV): ballot items · votes by manager · column guide.